Back to top

Image: Bigstock

Pulmatrix Surges on License Agreement With Johnson & Johnson

Read MoreHide Full Article

Pulmatrix, Inc. PULM announced that it has inked a licensing and development agreement with the Lung Cancer Initiative at Johnson & Johnson JNJ. The agreement grants the Lung Cancer Initiative an option to gain rights to Pulmatrix’s portfolio of narrow spectrum kinase inhibitors, including an early-stage candidate PUR1800. These candidates are intended to be developed for lung cancer interception.

Per the terms of the agreement, Pulmatrix will receive $7.2 million in upfront payment and is eligible to receive additional $2 million in milestone payments on completion of an early-stage clinical study on PUR1800. The study is expected to be completed by 2020-end. Moreover, if the Lung Cancer Initiative exercises its option to gain rights to the portfolio of narrow spectrum kinase inhibitors, Pulmatrix will be eligible to receive $91 million in development and commercial milestones. The company will also be eligible to receive royalty payments.

Shares of Pulmatrix surged 88.4%, following the deal announcement. This is because the deal is expected to boost its cash resources, which will likely support future clinical activities. On its third-quarter earnings call, the company had stated that it lacks sufficient funds to support clinical activities for any of its pipeline candidates beyond third-quarter 2020. Shares of the company have declined 50.7% in the past year against the industry’s increase of 3.8%.


Pulmatrix is a clinical stage biopharmaceutical company, which is focused on developing inhaled therapies for treating serious pulmonary disease using its patented iSPERSE technology.

We note that the company had in-licensed a portfolio of novel drug candidates consisting of kinase inhibitors from a wholly owned subsidiary of J&J in 2017. The company stated in its press release that it has unlocked clinical potential of PUR1800 using its iSPERSE technology. The candidate is intended to be developed for treating acute exacerbations in patients with COPD and is currently being evaluated in a phase Ib study.

Apart from PUR1800, the company has other pipeline candidates using iSPERSE technology in clinical development, which includes Pulmazole. An inhaled formulation of the anti-fungal drug itraconazole, Pulmazole is the most advanced candidate, which is being developed in a phase II study for treating allergic bronchopulmonary aspergillosis in patients with asthma.

Zacks Rank & Key Picks

Pulmatrix currently carries a Zacks Rank #2 (Buy).

A couple of other top-ranked stocks from the biotech sector include Coherus BioSciences, Inc. (CHRS - Free Report) and Agenus Inc. AGEN, both sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Coherus’ earnings estimates increased from $1.25 to $1.67 for 2020 over the past 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, the average beat being 149.94%. Shares of the company have gained 111.3% in the past year.

Agenus’ loss estimates have narrowed from $1.63 to $1.41 for 2020 over the past 60 days. The company delivered a positive earnings surprise in two of the trailing four quarters, the average beat being 23.79%. Share price of the company has increased 36.1% in the past year.

Biggest Tech Breakthrough in a Generation

Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.

A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.

See 8 breakthrough stocks now>>

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Coherus BioSciences, Inc. (CHRS) - free report >>